These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15670067)

  • 1. More on: does the factor V Asp79His (409 G/C) polymorphism influence Factor V and APC resistance levels?
    Bossone A; Margaglione M
    J Thromb Haemost; 2005 Feb; 3(2):417. PubMed ID: 15670067
    [No Abstract]   [Full Text] [Related]  

  • 2. Does factor V Asp79His (409 G/C) polymorphism influence factor V and APC resistance levels?
    Lunghi B; Scanavini D; Girelli D; Legnani C; Bernardi F
    J Thromb Haemost; 2005 Feb; 3(2):415-6. PubMed ID: 15670066
    [No Abstract]   [Full Text] [Related]  

  • 3. The factor V (FV) gene ASP79HIS polymorphism modulates FV plasma levels and affects the activated protein C resistance phenotype in presence of the FV Leiden mutation.
    Bossone A; Cappucci F; D'Andrea G; Brancaccio V; Cibelli G; Iannaccone L; Grandone E; Margaglione M
    Haematologica; 2003 Mar; 88(3):286-9. PubMed ID: 12651267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
    de Visser MC; Guasch JF; Kamphuisen PW; Vos HL; Rosendaal FR; Bertina RM
    Thromb Haemost; 2000 Apr; 83(4):577-82. PubMed ID: 10780320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
    Graf LL; Welsh CH; Qamar Z; Marlar RA
    Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic modulation of the FV(Leiden)/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes.
    Segers O; Simioni P; Tormene D; Bulato C; Gavasso S; Rosing J; Castoldi E
    J Thromb Haemost; 2012 Jan; 10(1):73-80. PubMed ID: 22044617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism.
    Bergrem A; Dahm AE; Jacobsen AF; Mowinckel MC; Sandvik L; Sandset PM
    Br J Haematol; 2011 Jul; 154(2):241-7. PubMed ID: 21564075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two novel factor V null mutations associated with activated protein C resistance phenotype/genotype discrepancy.
    Dargaud Y; Trzeciak MC; Meunier S; Angei C; Pellechia D; Négrier C; Vinciguerra C
    Br J Haematol; 2003 Oct; 123(2):342-5. PubMed ID: 14531918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Method-dependent influence of certain polymorphisms in the factor V B-domain on the response to activated protein C.
    Siegert G; Kostka H; Gehrisch S; Schwarz T; Schellong S; Jaross W
    Blood Coagul Fibrinolysis; 2000 Sep; 11(6):519-27. PubMed ID: 10997791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incidence of factor V Leiden in a normal Irish population and its relationship to the laboratory diagnosis of APC resistance.
    Vaughan J; Power C; Nolan C; McCarthy D; Shirley I
    Thromb Haemost; 1999 Apr; 81(4):661-3. PubMed ID: 10235460
    [No Abstract]   [Full Text] [Related]  

  • 11. Modulation of factor V levels in plasma by polymorphisms in the C2 domain.
    Scanavini D; Girelli D; Lunghi B; Martinelli N; Legnani C; Pinotti M; Palareti G; Bernardi F
    Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):200-6. PubMed ID: 14656739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of polymorphisms in the B-domain of factor V gene in APC-resistant patients.
    Kostka H; Siegert G; Schwarz T; Gehrisch S; Kuhlisch E; Schellong S; Jaross W
    Thromb Res; 2000 Sep; 99(6):539-47. PubMed ID: 10974338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotype and genotype expression in pseudohomozygous R2 factor V.
    Kalafatis M; Simioni P; Bernardi F
    Blood; 2001 Sep; 98(6):1988-9. PubMed ID: 11565539
    [No Abstract]   [Full Text] [Related]  

  • 14. A gene-centric analysis of activated partial thromboplastin time and activated protein C resistance using the HumanCVD focused genotyping array.
    Gaunt TR; Lowe GD; Lawlor DA; Casas JP; Day IN
    Eur J Hum Genet; 2013 Jul; 21(7):779-83. PubMed ID: 23188048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genetic polymorphisms associated with thrombophilia and risk for developing HELLP syndrome].
    Stiefel P; Miranda ML; Gómez De Rueda F; Muñoz-Hernández R
    Med Clin (Barc); 2013 Jan; 140(1):42-3. PubMed ID: 22766051
    [No Abstract]   [Full Text] [Related]  

  • 16. FV and APC resistance: the plot thickens.
    Castoldi E
    Blood; 2014 Apr; 123(15):2288-9. PubMed ID: 24723678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated protein C (APC) resistance: considerations about the importance of using the original and modified methods in thrombophilic disease.
    Gennari L; Blanco AN; Bermejo E; Salviú J; Grosso S; Lazzari MA
    Thromb Haemost; 2000 Jul; 84(1):138-9. PubMed ID: 10928486
    [No Abstract]   [Full Text] [Related]  

  • 18. Activated protein C resistance assay and factor V Leiden.
    Prüller F; Weiss EC; Raggam RB; Cervar-Zivkovic M; Renner W; Wagner J; Michaelis S; März W; Mangge H
    N Engl J Med; 2014 Aug; 371(7):685-6. PubMed ID: 25119624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [One Chinese case of F V Leiden mutation associated with APC resistance].
    Wu J; Gu JM; Morrisey JH; Esmon N
    Zhonghua Xue Ye Xue Za Zhi; 1997 Sep; 18(9):453-6. PubMed ID: 15625834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention of thrombosis in genetic susceptibility? Thrombosis ABC: APC resistance].
    Stiefelhagen P
    MMW Fortschr Med; 1999 Sep; 141(35):44. PubMed ID: 10897957
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.